Benjamin Jordan Cohn - 07 Apr 2026 Form 4 Insider Report for HOLOGIC INC (HOLX)

Reporting relationship: Principal Accounting Officer
Issuer ticker: HOLX
Reported as of: 07 Apr 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 09 Apr 2026, 17:01:08 UTC
Prior SEC filing: 18 Nov 2025
Source filing: View source filing
Reporting owner signature: /s/ Mark W. Irving, attorney-in-fact for Mr. Cohn

Key filing fact

Benjamin Jordan Cohn filed Form 4 for HOLOGIC INC (HOLX) on 09 Apr 2026.

Key facts

This page summarizes Benjamin Jordan Cohn's Form 4 filing for HOLOGIC INC (HOLX).
9 reported transactions and 8 derivative rows are listed below.
Accepted by SEC: 09 Apr 2026, 17:01.

Change

Previous filing in this sequence was filed on 18 Nov 2025.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001748821 Primary reporting owner

COHN BENJAMIN JORDAN

Relationship: Principal Accounting Officer
Address: 250 CAMPUS DRIVE, MARLBOROUGH
Signature: /s/ Mark W. Irving, attorney-in-fact for Mr. Cohn
Signature date: 09 Apr 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

HOLX transaction

Common Stock

Disposed to Issuer

Transaction value
Shares: -17,964
Change %: -100%
Price
Shares after: 0
Date: 07 Apr 2026
Ownership: Direct
Footnotes: F1, F2, F3

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

HOLX transaction Derivative

Non-qualified Stock Option (Right to Buy)

Disposed to Issuer

Transaction value
Shares: -10,861
Change %: -100%
Price
Shares after: 0
Date: 07 Apr 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 10,861
Exercise price: $45.61
Footnotes: F4

HOLX transaction Derivative

Non-qualified Stock Option (Right to Buy)

Disposed to Issuer

Transaction value
Shares: -7,505
Change %: -100%
Price
Shares after: 0
Date: 07 Apr 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 7,505
Exercise price: $68.35
Footnotes: F4

HOLX transaction Derivative

Non-qualified Stock Option (Right to Buy)

Disposed to Issuer

Transaction value
Shares: -7,132
Change %: -100%
Price
Shares after: 0
Date: 07 Apr 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 7,132
Exercise price: $71.13
Footnotes: F4

HOLX transaction Derivative

Non-qualified Stock Option (Right to Buy)

Disposed to Issuer

Transaction value
Shares: -3,382
Change %: -100%
Price
Shares after: 0
Date: 07 Apr 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 3,382
Exercise price: $74.35
Footnotes: F4

HOLX transaction Derivative

Non-qualified Stock Option (Right to Buy)

Disposed to Issuer

Transaction value
Shares: -3,509
Change %: -100%
Price
Shares after: 0
Date: 07 Apr 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 3,509
Exercise price: $71.94
Footnotes: F4

HOLX transaction Derivative

Non-qualified Stock Option (Right to Buy)

Disposed to Issuer

Transaction value
Shares: -3,505
Change %: -100%
Price
Shares after: 0
Date: 07 Apr 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 3,505
Exercise price: $79.39
Footnotes: F4

HOLX transaction Derivative

Performance Stock Units

Award

Transaction value
Shares: +5,665
Change %
Price
Shares after: 5,665
Date: 07 Apr 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 5,665
Exercise price
Footnotes: F5, F6

HOLX transaction Derivative

Performance Stock Units

Disposed to Issuer

Transaction value
Shares: -5,665
Change %: -100%
Price
Shares after: 0
Date: 07 Apr 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 5,665
Exercise price
Footnotes: F5, F6

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Section 16 status

Benjamin Jordan Cohn is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may still apply in specific circumstances.

Explanation of responses 6 footnotes

Footnote F1

Includes 80 shares of common stock acquired pursuant to Hologic's employee stock purchase plan since the date of the reporting person's most recently filed Form 4.

Footnote F2

Pursuant to the Agreement and Plan of Merger, dated as of October 21, 2025 (the "Merger Agreement"), by and among Hologic, Inc. ("Hologic" or "Company"), Hopper Parent Inc., a Delaware corporation ("Parent"), and Hopper Merger Sub Inc., a Delaware corporation and wholly owned subsidiary of Parent ("Merger Sub"), Merger Sub merged with and into the Company (the "Merger"), with the Company surviving the Merger as a wholly owned subsidiary of Parent. At the effective time of the Merger (the "Effective Time"), each share of Hologic common stock, par value $0.01 ("Company Common Stock"), was converted into the right to receive (x) $76.00 per share in cash, without interest (the "Cash Consideration") and (y) one (1) contingent value right, which represents the right to receive up to $3.00 in cash, when and if payable (each, a "CVR") (the consideration contemplated by clauses (x) and (y), together, the "Merger Consideration").

Footnote F3

At the Effective Time, each time-vesting restricted stock unit award ("Company RSU") held by the reporting person granted before October 21, 2025 converted into the right to receive the Merger Consideration for each share of Company Common Stock underlying the Company RSU; and each Company RSU held by the reporting person granted after October 21, 2025 converted into, for each share of Company Common Stock subject to such Company RSU immediately prior to the Effective Time, (i) an unvested award representing the right to receive a cash payment equal to the Cash Consideration, and (ii) an unvested award representing the right to receive cash payments equal to the payments to the holder of one CVR, if any, pursuant to the CVR agreement, in each case, subject to the terms applied to the corresponding Company RSU immediately prior to the Effective Time. As a result of the Merger, the reporting person no longer beneficially owns, directly or indirectly, any shares of Company Common Stock.

Footnote F4

For Footnote (4), see Remarks below.

Footnote F5

Each Hologic restricted stock unit represents a contingent right to receive one share of Company Common Stock.

Footnote F6

Represents the certification of performance results applicable to outstanding Hologic performance stock units ("PSUs") by the compensation committee of the board of directors of Hologic. Pursuant to the Merger Agreement, for purposes of determining the number of shares of Company Common Stock subject to each PSU, any applicable performance goals were deemed achieved at the greater of (A) the target level of performance and (B) the actual level of performance measured through the latest practicable date prior to the Effective Time. Pursuant to the Merger Agreement, each outstanding PSU was cancelled and converted into the right to receive the Merger Consideration in respect of each share of Company Common Stock subject to such PSU.

SEC remarks

(4) Pursuant to the Merger Agreement, each outstanding option to purchase shares of Company Common Stock (a "Company Option") with an exercise price per share less than the Cash Consideration was cancelled and converted into the right to receive (i) an amount in cash equal to the product of (A) the number of shares of Company Common Stock subject to such Company Option, multiplied by (B) the excess of the Cash Consideration over the exercise price per share of the Company Option, and (ii) one CVR with respect to each share. Each outstanding Company Option with an exercise price per share equal to or greater than the Cash Consideration and less than the sum of the Cash Consideration and $3.00 was cancelled and converted into the right to receive one CVR with respect to each share of Company Common Stock subject to such Company Option, payment in respect of which will be net of the excess of the applicable exercise price per share of the Company Option over $76.00. Each outstanding Company Option with an exercise price per share of Company Common Stock equal to or greater than the sum of the Cash Consideration and $3.00 was cancelled for no consideration.